Federal watchdog looks at compounded GLP-1 oversight

The Department of Health and Human Services' Office of Inspector General, the federal agency responsible for independently auditing HHS programs, announced a new study this week examining how well the FDA has been overseeing the compounding of GLP-1 drugs.

The focus: how frequently FDA inspects compounding facilities and how effectively it uses available data to identify patient safety risks.

The backdrop is the 2022–2025 GLP-1 drug shortages, which legally allowed compounding facilities to produce copies of those drugs – and the question of whether some facilities are still compounding at scale now that those shortages have ended.

The project has an estimated completion date of fiscal year 2028, which tells you something about the scope. For legitimate, compliant compounding pharmacies, a rigorous federal review isn't something to fear – it's an opportunity to demonstrate that the regulated system works exactly as it should, and that bad actors operating outside it are the real problem worth investigating.